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Background: Regorafenib, a multi-kinase inhibitor, is used in the treatment of patients with metastatic colorectal
cancer refractory to standard therapy. However, this benefit was limited to 1.4 months improvement in overall
survival, with more than half of patients experiencing grade 3 to 4 adverse events. We aim to elucidate the
pharmacodynamic effects of regorafenib in metastatic colorectal cancer and discover potential biomarkers that may
predict clinical benefit.
Methods: Patients with metastatic colorectal adenocarcinoma refractory to standard therapy with tumours
amenable to biopsy were eligible for the study. Regorafenib was administered orally at 160 mg daily for 3 out
of 4 weeks with tumour assessment every 2 cycles. Metabolic response was assessed by FDG PET-CT scans
(pre-treatment and day 15); paired tumour biopsies (pre-treatment and day 21 post-treatment) were sampled for
immunohistochemistry and proteomic profiling analyses. Plasma circulating cell free DNA was quantified serially
before and after treatment.
Results: There were 2(6%) partial responses out of 35 patients, and 8(23%) patients had stable disease for more
than 7 months. Adverse event profile was similar to reported data. Recurrent somatic mutations in K-RAS, PIK3CA
and BRAF were detected in plasma circulating cell free DNA in 14 patients; some mutations were not found in
archival tumour. Total plasma circulating cell free DNA inversely correlated with progression free survival (PFS),
and presence of KRAS mutations associated with shorter PFS. Immunohistochemistry of pre- and post- treatment
biopsies showed majority of patients had downregulation of phosphorylated-VEGFR2, podoplanin, phosphorylated-
AKT, Ki-67 and upregulation of the MEK-ERK axis, phosphorylated-C-MET, phosphorylated-SRC, phosphorylated-
STAT3 and phosphorylated-JUN. Proteomic analysis of fine needle tumour aspirates showed down-regulation of
PI3K was associated with longer PFS.
Conclusion: Plasma circulating cell free DNA may yield potential predictive biomarkers of regorafenib treatment.
Downregulation of the PI3K-AKT axis may be an important predictor of clinical benefit.
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Regorafenib is a multi-kinase inhibitor with activity in na-
nomolar concentration range against VEGFR1-3, PDGFR,
C-KIT, RET, TIE-2, C-RAF, B-RAF, p38-αand FGFR1. [1]
A randomised phase III study of regorafenib against pla-
cebo and best supportive care in patients with refractory
colorectal carcinoma (CRC) including prior therapy with
bevacizumab, cetuximab or panitumumab in KRAS wild-
type tumours showed improvement of progression free
survival (PFS) as well as overall survival (OS) in favour of
regorafenib treatment, establishing a new standard of care
in this study population [2].However, OS benefit was a
modest 1.4 months, contributed mainly by disease control
rather than tumour shrinkage. Analysis of PFS and OS
plots clearly suggest a subpopulation of patients with
refractory CRC that would benefit from regorafenib the-
rapy. Regorafenib therapy carries potential risk of adverse
events including hepatotoxicity, haemorrhage, hand-foot
syndrome, coronary syndromes, and reversible posterior
leukoencephalopathy syndrome. In the pivotal phase III
study, 61% of patients had dose interruption, 38% had
dose reduction, and 8.2% discontinued therapy due to
adverse events. Therefore, better selection of patients
through elucidation of the mechanism of action of
regorafenib and development of biomarkers to predict
clinical benefit is critical. We designed an open label
study of regorafenib in Asian patients with metastatic
refractory CRC to determine the molecular underpinnings
of regorafenib treatment as well as to develop biomarkers
that could potentially predict clinical benefit.
Methods
Patient eligibility
Eligible patients had histologically verified, biopsy amen-
able metastatic colorectal adenocarcinoma refractory to
standard therapy and not amenable to surgery with cu-
rative intent. Biopsy amenable was defined as ≥1 lesion
suitable for repeated biopsy; e.g. subcutaneous nodule,
skin lesion, rectal tumour, colonic mass easily reached
by colonoscopy, peritoneal masses ≥3 cm in maximum
diameter easily assessable by image guided core biopsy,
or liver lesions ≥3 cm in maximum dimension with a rim
of normal liver tissue, accessible safely by image guided
core biopsy using an 18 F gauge needle as determined by
an experienced interventional radiologist. Other criteria
included ECOG (Eastern Cooperative Oncology Group)
Performance Score of 0–1, bone marrow function, liver
function and renal function within normal limits, and life
expectancy of ≥3 months. Patients were excluded if they
had undergone major surgery, chemotherapy, investiga-
tional therapy or radiotherapy within 28 days of start of
regorafenib, severe illnesses or malabsorption. All patients
gave written informed consent and the study was
approved by the Domain Specific Ethics Review Boardof the National Healthcare Group, Singapore and the
Health Sciences Authority of Singapore (Clinicaltrials.gov
identifier NCT1189903).
Materials and methods
The study was an open-label study conducted at the
National University Cancer Institute, Singapore. Regorafenib
tablets (40 mg) were supplied by Bayer Healthcare Berlin,
Germany and administered orally after breakfast at a star-
ting dose of 160 mg daily for 21 days followed by 7 days
without dosing per 28-day cycle. Dosing was continued
until disease progression, occurrence of unacceptable tox-
icity, withdrawal of consent or withdrawal at physician’s
discretion. Plasma samples were collected on cycle 1 day
1, cycle 1 day 8 and cycle 2 day 21 prior to dosing for cir-
culating cell free DNA analysis. Tumour biopsies were
performed using 18G core biopsy needles limited to 1–2
passes for each sample to reduce risk of haemorrhage and
fine needle aspirations using 23G needles with immediate
bedside cytopathological confirmation of presence of tu-
mour cells; biopsies were done within 1 week of initiating
regorafenib, and repeated on day 21. Tumour biopsies
were processed according to procedures detailed below.
Immunohistochemistry (IHC) analysis of tumour sam-
ples were performed at Mosaic Laboratories (Lake Forest,
California, USA). Fine needle aspirates were stored in
Protein Later® in glass cryovials and shipped to Prome-
theus Laboratories (San Diego, California, USA). Pro-
teomic analysis and quantitation from aspirates were
performed by Collaborative Enzyme Enhanced Reactive
Immunoassay (CEER).
Dose interruptions were permitted for adverse events
of grade 2 or higher; up to 2 dose reductions were allowed
in each patient for toxicities of grade 3 or 4.
Tissue microscopy and IHC on formalin fixed, paraffin
embedded tissues
Fifty-five samples were stained with H&E, and stained
slides were evaluated by a pathologist for presence and
percentage of tumour and necrosis. IHC was performed
in accordance with Mosaic Laboratories’ standard opera-
ting procedures (SOP).
Stained slides were reviewed by image analysis (Image
Scoop software, Aperio, Vista CA) for CD31, podoplanin,
and Ki-67. The final output for CD31 and Ki-67 was total
percent positive staining using Aperio algorithms. The
final output for podoplanin was a hotspot count of three
areas of lymphatic vessels. Areas with the highest amount
of lymphatic vessels were identified and three fields at 20x
magnification were selected for manual enumeration.
All other stains were reviewed by a pathologist blinded
to patient treatment. Pathology review consisted of a semi-
quantitative evaluation of staining in the tumour at four
levels: 0 (unstained), 1+ (weak staining), 2+ (moderate
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ing and H-Score were calculated based on the summation
of the product of percent of cells stained at each intensity
using the following equation: (3 × % cells staining at 3+) +
(2 × % cells staining at 2+) + (1 × % cells staining at 1+).
Both nuclear and cytoplasmic staining were factored into
the H score.
IHC stains used included phosphorylated VEGFR2
(pVEGFR2), total VEGFR2, phosphorylated ERK (pERK),
total ERK, CD31, phosphorylated c-Kit (pKIT), total
c-Kit, phosphorylated MEK (pMEK), phosphorylated
JUN (pJUN), phosphorylated JNK (pJNK), podoplanin,
phosphorylated STAT3 (pSTAT3), total STAT3, phospho-
rylated AKT (pAKT), total AKT, phosphorylated MET
(pMET), cMET, HGF, phosphorylated p70 S6 kinase
Thr389 (pp70S6K), phosphorylated SRC (pSRC), and total
SRC. All IHC assays have been optimized and validated
for use in human tissue. All tissues were screened by
H&E and a subset of suitable samples were screened by
IHC.
Details of IHC antibodies are elaborated in Additional 1.
Analysis of plasma circulating cell free DNA
Fourteen somatic mutations were analysed in DNA iso-
lated from plasma samples obtained on cycle 1 day 1
prior to treatment, cycle 1 day 8, and cycle 2 day 21.
The list of mutations studied were part of a panel of
genes specific for colorectal cancer (Additional file 2:
Table S1). Analysis was done using BEAMing (Beads,
Emulsions, Amplification and Magnetics) technology at
InosticsGmBH, Hamburg, Germany [3]. Plasma samples
are first thawed at room temperature before DNA pre-
paration, with cell debris removed by centrifugation. The
QIAamp CAN purification kit was then used for isolation
of free circulating DNA from plasma samples. Quantifica-
tion was done using a modified version of human LINE-1
qRT-PCR. Human LINE-1 sequence-based assay, rather
than individual genes, was chosen to measure DNA yield
after DNA isolation as it required a smaller amount of
starting material. Each sample and reference standard
were run in duplicate. Isolated plasma DNA was then pre-
amplificed under high-fidelity PCR conditions, and PCR
products were quality checked on an agarose gel. The
resultant pre-amplified DNA was then utilised for sub-
sequent BEAMing assay. Normalized amounts of pre-
amplified DNA was then further amplified on magnetic
bead surfaces in water in oil-emulsions, and hybridized
to fluorescent labelled mutation specific probes and
subjected to flow cytometry to quantify the fraction of
mutant to wild-type DNA alleles. This fraction is calcu-
lated by dividing the amount of mutant beads by total
amount of beads with PCR product, with lower detec-
tion limit at mutant fraction of 0.02%. Total circulating
cell free DNA included non-mutant and mutant DNAfrom tumour as well as non-mutant, non-tumour derived
DNA. Quantification of DNA content was expressed as
genome equivalents (GE), where 1 GE is one haploid
genome weighing 3.3 pg.
Collaborative enzyme enhanced reactivity (CEER) analysis
Tumour fine needle aspirates (FNAs) obtained with
23G gauge needle were placed in ProteinLater® solution
and shipped to Prometheus Laboratories (Prometheus
Laboratories, San Diego, CA) for further processing and
analysis as described previously [4]. Protein lysates were
prepared according to a SOP which included tissue
homogenization and collection of supernatants following
centrifugation at 16,000 rpm for 15 minutes at 4°C. Pro-
tein concentrations were determined using bicinchoni-
nic acid (BCA) assay and protein lysates were aliquoted
and stored at −70°C prior to CEER analysis. CEER is a
proximity-based immunoassay suitable for analysing both
total protein expression levels and activation status of
protein signalling cascades of interest.
Tumour imaging
Patients underwent fluorodeoxyglucose (FDG) PET-CT
scans within a week before starting regorafenib and on
day 15 of cycle 1. Tumour standardized uptake values
(SUV) were measured according to standardized image
acquisition protocols and assessed according to EORTC
criteria for response. Tumour measurements were made
according to RECIST 1.1 and compared every 2 cycles.
Statistical analysis
This was an exploratory study and sample size was based
on obtaining 12 to 14 paired samples suitable for IHC
with an expected attrition rate of 60%. Descriptive statis-
tics were used to present data on each biomarker in the
study. PFS was defined as the time from starting treat-
ment to clinical or radiological progression or death,
whichever occurred first. Correlation between variables
was performed using Pearson correlation coefficient
analysis. To study the effect of change in each protein
biomarker after treatment on PFS, comparison of PFS
between patients with up- or down-regulated biomarkers
was done using non-parametric Mann Whitney U test.
The log-rank test was used to compare PFS distributions
for KRAS mutation status or changes in biomarker levels
after regorafenib treatment. All statistical analyses were
done using IBM SPSS Statistics version 21.0.
Results
Drug efficacy
Thirty-seven patients were enrolled; 2 failed screening
and 35 received at least one dose of regorafenib. As ex-
pected, in this population of refractory CRC patients,
49% had 4 or more prior chemotherapy regimens and
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treatment (Table 1). Figure 1 shows the CONSORT dia-
gram of patients’ treatment, tumour response evaluation
and tumour biopsies obtained. Twenty-eight patients
were evaluable for response, with best response of 2 par-
tial responses (PR) and 18 patients with stable disease
(SD), resulting in a disease control rate (DCR) at 8 weeks
of 57% by intent-to-treat analysis. Median PFS was
105 days (range 17–484 days); 8(23%) patients remained
progression-free for 217 days or longer. Patients had
similar PFS regardless of prior treatment with bevacizumab
(log rank test p = 0.758).
Twenty-nine patients had paired FDG PET-CT scans,
and 15 (52%) patients had partial or complete meta-
bolic response on cycle 1 day 15 according to EORTC
criteria, although there was no correlation between day
15FDG PET SUV response and DCR (p = 1.0) or PFS























AST (U/L) 34.6 ± 22.4
ALT (U/L) 23.5 ± 10.9
Total bilirubin (μmol/L) 10.1 ± 5.8
Creatinine (μmol/L) 66.9 ± 27.0
37 patients screened; 35 commenced therapy, 2 failed screening.
8 patients did not complete cycle 2 for tumour biopsy and evaluation
of response.
11 patients did not have second biopsy.Adverse events
The toxicity profile of regorafenib was consistent with
previous reports, commonest included fatigue, hand-
foot syndrome (HFS), diarrhea, and hypophonation oc-
curring in more than 30% of patients. Three deaths were
considered treatment-related, all occurring in cycle 1,
including acute myocardial infarction, disseminated
intravascular coagulation and bowel perforation. Ten
other patients developed toxicities in cycle 1 requiring
dose reduction or discontinuation of treatment. There
were no biopsy related complications. Median relative
dose intensity was 79%, with 43% of patients requiring
dose reduction, and 60% of patients requiring at least
one dose interruption.
Plasma circulating cell free DNA
Fourteen patients had quantifiable plasma circulating
tumour mutant DNA on cycle 1 day 1 prior to treat-
ment, and underwent quantification of total (derived
from tumour and non-tumour tissues) as well as mutant
DNA copies (from tumour tissues) on cycle 1 day 8 and
cycle 2 day 21. Mutations detected included KRAS mu-
tations (n = 14, 40%), PIK3CA mutations (n = 4, 11%)
and BRAF (n = 3, 9%), consistent with reported frequen-
cies. Percentage of mutant KRAS DNA ranged from
0.03% to 54%. Four patients had mutations that were not
found in available archival tumour tissue (archival tissue
available for 26 patients); 3 were PIK3CA mutations, and
1 had multiple mutations in BRAF, KRAS and NRAS.
These could reflect tumour heterogeneity, genetic evo-
lution of the tumour with treatment, or both. Two pa-
tients who received prior cetuximab treatment (patient
19 and 35) did not have detectable KRAS mutations in
archival tissue, but had multiple KRAS mutations in
plasma cell free DNA occurring in low frequency.
Total circulating cell free DNA at baseline inversely
correlated with PFS; r = 0.537, p = 0.048 (Figure 2). Total
plasma DNA remained lower in patients with longer
PFS even after regorafenib treatment (Additional file 3:
Figure S1). Baseline mutant DNA copy number and per-
centage (%) mutant DNA were not predictive of PFS;
r = −0.38, p = 0.18 and r = −0.27, p = 0.35, respectively.
Patients with detectable KRAS mutations in circula-
ting cell free DNA had shorter PFS compared to pa-
tients with undetectable KRAS mutations (mean PFS
105 days [95% CI 58–152 days] vs 217 days [95% CI
76–358 days] p = 0.04). Additional file 3: Figure S2
shows trends of % mutant DNA with time in patients
with PFS below compared to above median PFS. All
except 1 patient (patient 13) with longer PFS had early
decline in mutant DNA fraction and remained at a low
level, whereas patients with shorter PFS had increased
or little change in mutant DNA fraction at day 8. Pa-
tients 19, 26 and 33 in the latter group had fall in
Figure 1 37 patients with refractory colorectal cancer.
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response on PET CT on day 15.
Immunohistochemistry changes in tumour before and
after regorafenib
After assessing the quality of tissue obtained and repre-
sentativeness of tumour samples on H&E stains, 10 out
of 25 paired samples were suitable for analysis for tumour
effects of regorafenib treatment. Figure 3 summarises
changes in H-scores in post-treatment samples com-
pared to baseline. pVEGFR-2, podoplanin, CD31, Ki67,
pKIT, pAKT, c-MET, STAT3 and HGF were downregu-
lated whereas pMET, pMEK, pSRC, pSTAT3 and pJUN
were upregulated in majority of patients. Selected IHC
results for patients 20 and 27 are illustrated in Figure 4,
reflecting increased and reduced expression for pVEGFR-2,
Ki67, pAKT, pc-MET, pJUN and pSRC.Figure 2 Correlation between PFS and baseline total cell free DNA.Proteomic analysis of tumour aspirates
Tumour aspirates preserved in ProteinLater® were ana-
lysed on a printed array panel format, with each im-
munoassay normalised to cytokeratin expression and
measured in computed units (CU). We chose proteins
available on the panel and considered relevant to mo-
lecular targets of regorafenib or commonly activated sig-
nalling pathways in colorectal cancer. Fourteen paired
samples were analysed, and changes in expression were
compared before and after treatment. To evaluate pre-
dictors for PFS, log-rank analyses of PFS between patients
with up- or down-regulation (defined as ≥20% increase or
decrease in CU score post treatment) of each protein co-
variable were performed. Down regulation of PI3K was
observed in 10/14 (71%) of patients and associated with
prolonged PFS (median PFS 252 days in down regulated
vs 49 days in unregulated patients; log rank p = 0.01)
Figure 3 Changes in immunohistochemistry with regorafenibtreatment.
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proteins in the tumour aspirate after treatment with re-
gorafenib. We correlated changes in protein expression
according to metabolic response, and found that down-
regulation of the phosphorylated-proline rich AKT sub-
strate (pPRAS) was seen in all patients with metabolic
response (n = 8), compared to 25% of patients without
metabolic response (n = 4, Fishers exact test p = 0.018).
Discussion
Regorafenib had similar efficacy and toxicity profile in this
study as presented in the CORRECT study [2]. Treament
related mortalities were observed and dose reduction for
toxicities was common in the first cycle. Nonetheless, as a
substantial proportion of patients experienced significant
clinical benefit, it is critical to characterise this subgroup.
Compared to the CORRECT study where all patients had
prior bevacizumab, 43% of patients had prior bevacizumab
in this study; clinical benefit was similar with or without
bevacizumab. This study provided some biomarker leads
regarding patients who have longer PFS and a potential
mechanism of resistance to regorafenib through the PI3K-
AKT pathway of signalling.
Circulating cell free DNA analysis identified mutant
KRAS, PIK3CA and BRAF with frequencies consistent
with reported literature and wide interindividual varia-
bility of mutant fractions [5-7]. New mutations in RAS
and PIK3CA emerged after therapy compared to archival
tumour, and the emergence of multiple KRAS mutations
in low levels after anti-EGFR therapy is a known resistance
mechanism to anti-EGFR antibodies [8]. These findingsraise the possibility of evaluating mechanism-based treat-
ments like MEK inhibitors and PI3K inhibitors in these
patients with cetuximab resistance according to detection
of KRAS or PIK3CA mutations in plasma cell free DNA,
respectively.
There has been controversy regarding the use of cell
free DNA fractions as predictive biomarkers; both total
circulating DNA and mutant fractions have been corre-
lated with tumour response. Consistent with a previous
report, we found that total circulating cell free DNA
levels correlated inversely with PFS Total plasma cell free
DNA includes DNA from both mutant and non-mutant
tumour cells, and non-tumour cells, and thus may be a
better representation of the overall tumour burden in a
patient with metastatic cancer where variability of mutant
fraction exists due to tumour heterogeneity. Our data and
findings from renal cell carcinoma support this finding
[9,10]. Furthermore, as tumour subclones vary in sensitiv-
ity to treatment, circulating mutant DNA derived from
tumour subclones may not be an accurate reflection of
overall tumour burden. On the other hand, quantitation
of circulating mutant DNA showed early decrease in the
mutant fraction in patients with longer PFS, suggesting
that in colorectal carcinoma, early reduction in the more
aggressive mutant clones could prolong disease control.
This observation is consistent with previous studies in
CRC patients undergoing surgery where complete resec-
tions resulted in a sharp drop in circulating mutant DNA
24 hours after surgery, and in breast cancer patients where
a reduction in mutant DNA tumour fraction correlated







Figure 4 Immunohistochemistry of selected proteins of representative samples before and after regorafenib treatment. Patient 27:
pVEGFR2 staining shoes a reduced H score of pre-trearment-35 (A1: 5% 2+; 30% 1 + staining) to post-treatment-20 (A2: 5% 2+; 15% 1+ staining)
in a small proportion of tumor cells. Arrows denote reduced proportion of tumor cells with 1+ staining between pre and post-treatment samples.
Patient 20: Ki67 staining shows reduced expression of pre-treatment (B1: 63%) to post-treatment (B2: 26%); pAKT staining shows a reduced
H score of pre-treatment-10 (C1: 6% 3+; 2% 2+; 2% 1+; 90% 0) to post-treatment (C2: 2% 3+; 8% 2+; 10% 1+; 80% 0); pcMET staining shows an
increased H score of pre-treatment-80 (D1: 0% 3+; 2%+; 78% 1+; 20% 0) to post-treatment -95 (D2: 20% 3+; 5% 2+; 70% 1 + 5% 0); pJUN staining
shows an increased H score of pre-treatment-5 (E1: 0% 3+; 0% 2+; 5% 1+; 95% 0) to post-treatmetn-50 (E2: 2% 3+; 13% 2+; 35% 1+; 50% 0);
pSRC staining shows an increased H score of pre-treatmetn-3 (F1: )% 3+; 0% 2+; 3% 1+; 97% 0) to post-treatment-35 (F2: 15% 3+; 10% 2+;
10% 1+; 65% 0). Only staining in tumor cells was scored, background and stromal staining was ignored.
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showed that regorafenib targets tumour stromal vascu-
lature through down regulation of VEGFR-2 phospho-
rylation and podoplanin. However, several signalling
pathways including expected targets of regorafenib were
upregulated, perhaps suggesting alternative pathways were
activated in response to regorafenib [12]. For example, the
up regulation of pMEK and lack of suppression of ERK
phosphorylation was surprising given both VEGFR-2 andRAF are inhibited by regorafenib. Nonetheless, this is
consistent with in vitro studies that show early decrease in
pERK upon initial exposure, followed by increase upon
longer exposure to regorafenib with increased MEK phos-
phorylation [13]. Only the AKT pathway appeared to be
downregulated consistently from regorafenib treatment.
In cell lines, regorafenib has been shown to induce
endoplasmic reticulum stress, and the observation that
regorafenib treatment activated JUN in most patients is
Figure 5 Progression free survival of patients according to change in PI3K expression.
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patocellular cell lines where treatment with regorafenib
resulted in upregulation of pJNK [13,14].
CEER analysis indicate the importance of the PI3K-
AKT-mTOR axis in mediating tumour survival mecha-
nisms, as PI3K down regulation in 71% of patients and was
associated with longer PFS and metabolic responses were









BRAF 385 -99.5 -97.1
Wt 275 -46.3 -75.3
KRAS + PIK3CA 274 -39.7 54.9
Wt 252 -97.7 0
Wt 484 -86 -86.8
Wt 236 -63.2 -96.7
Wt 109 -99.8 0
BRAF 106 483.3 97.3
NRAS 106 -92.7 -96.8
KRAS + PIK3CA 105 -99.9 0
KRAS 48 36020 -38.3
KRAS 47 180 770
BRAF + KRAS 49 159.7 -96.5





Negative % change reflects downregulation; positive % change reflects upregulatio
*Mann Whitney U test (2-tailed) of PFS between patient populations with upregulatThe patient samples studied were limited, however, these
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markers. If so, biomarkers in this pathway could inform
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treatment with regorafenib and PI3K-AKT-mTOR inhi-
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suggests a role for combination of regorafenib with either a
PI3K or AKT inhibitor in patients whose tumours activate
PI3K-AKT following regorafenib treatment. We have initi-
ated preclinical studies to understand mechanistically the
role of inhibitors of the PI3K-AKT-mTOR axis in relation
to regorafenib treatment in colorectal carcinoma cell lines,
and if promising, will proceed to a clinical trial of addition
of a PI3K or AKT inhibitor in patients with metastatic
colorectal carcinoma who have demonstrated refractori-
ness to regorafenib, selected on the basis of up regulation
of the PI3K/AKTaxis.
Conclusion
In conclusion, this study raises several important hy-
potheses including whether circulating cell free DNA
information could be utilised to monitor patients’ re-
sponse to regorafenib therapy, and to guide additional
treatment directed against emergence of new onco-
genic mutations, as well as the role of the PI3K-AKT
pathway in resistance to regorafenib. We believe that
these questions should be the subject of future cli-
nical trials.
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